pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Parabilis Medicines

updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
zolucatetide
Craniopharyngioma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Parabilis Medicines jobs →

News

  • Windward nets $175M IPO, bringing 2026 biotech debuts to 35
    Windward Bio’s public debut brings this year’s IPO count well above the sluggish total of eight in 2025.
    biospace · 6d ago
  • Once undruggable, the Wnt/B-catenin pathway shows increasing promise
    Early-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types.
    biospace · 20d ago
  • Biotech IPOs raise $7.5B as sector’s performance rally flattens
    While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-sp…
    biospace · 24d ago
  • Protein degrader specialist Lycia prices $318M IPO
    Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
    biopharma_dive · 27d ago
  • Biotech notches 31 IPOs already this year, with 4 more joining queue
    The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…
    biospace · 28d ago
  • City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
    City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.
    biospace · 1mo ago
  • Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
    Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.
    fiercebiotech · 1mo ago
  • The 2026 Biotech Graveyard
    Fierce’s biotech graveyard is an annual tradition in which we remember all the companies we lost over the past year. While we're embracing the spooky spirit of Halloween, we hope the sad stories of…
    fiercebiotech · 1mo ago
  • Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
    Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.
    fiercebiotech · 1mo ago
  • Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
    Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals brought in $116.7 million and $45 million from their respective IPOs, continuing a bumper year for biotech listings.
    fiercebiotech · 1mo ago
view all news mentions →
identifiers
source
globaldata
top tags
NSCLC1Oncology1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?